GenMark Diagnostics Schedules First Quarter 2014 Financial Results Conference Call for May 6, 2014

CARLSBAD, Calif.--()--GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 6, 2014. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. EDT on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 35146653 approximately five minutes prior to the start time.

About GenMark

GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark's proprietary eSensorĀ® detection technology, GenMark's eSensorĀ® XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory Viral Panel, Thrombophilia Risk Test, and Warfarin Sensitivity Test. A number of other tests, including HCV Genotyping, 2C19 Genotyping, and 3A4/3A5 Genotyping are available for research use only. For more information, visit www.genmarkdx.com.

Contacts

GenMark Diagnostics, Inc.
Hany Massarany
President/Chief Executive Officer
760-448-4358

Sharing

Contacts

GenMark Diagnostics, Inc.
Hany Massarany
President/Chief Executive Officer
760-448-4358